ArticleCell death & disease2026
Exosomal miR-92a-3p promotes pancreatic cancer cells' extravasation by inducing vascular permeability through inhibition of DAB2IP.
Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- miR-27b-5p targets RAB27A to regulate exosome secretion and migration of pancreatic cancer cells.Translational cancer research · 2026Article
- Extracellular vesicles in heart failure: bridging pathogenic insights, diagnostic utility, and therapeutic applications.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Metastasis, the colonization of distant organs by cells derived from primary cancer, is the leading cause of mortality in pancreatic adenocarcinoma (PAAD). Growing evidence indicates that cancer-derived exosomes play pivotal roles in facilitating cancer metastasis by promoting pre-metastatic niche formation. However, the contribution of PAAD-derived exosomal microRNAs (MiRNAs) to this process remains poorly characterized. In this study, we identified specific PAAD-derived exosomal miRNAs involved in metastatic progression. Sequencing of small RNAs extracted from circulating exosomes derived from patients with metastatic or non-metastatic PAAD revealed that miR-92a-3p is associated with a metastatic phenotype. We demonstrated that exosomal miR-92a-3p facilitates cancer cells' extravasation and lung metastasis by disrupting vascular barrier integrity. Mechanistically, exosomal miR-92a-3p directly inhibits the tumor suppressor disabled homolog 2 interacting protein (DAB2IP), thereby activating the PI3K-AKT signaling cascade in endothelial cells (ECs). This activation attenuates expression of intracellular junction markers and stimulates endothelial nitric oxide synthase, leading to increased vascular permeability. Our findings suggest that targeting miR-92a-3p could represent a potential strategy to reduce metastasis in PAAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.